Last reviewed · How we verify
LYB001
At a glance
| Generic name | LYB001 |
|---|---|
| Sponsor | Yantai Patronus Biotech Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or Older (PHASE3)
- Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above (PHASE3)
- Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above (PHASE2)
- The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001 (EARLY_PHASE1)
- Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above (PHASE1)
- The Phase Ⅱ/Ⅲ Trial of LYB001 (PHASE2, PHASE3)
- Phase Ⅱ and Ⅲ Trial of a SARS-CoV-2 Vaccine LYB001 (PHASE2, PHASE3)
- A Phase Ⅰ Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine LYB001 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LYB001 CI brief — competitive landscape report
- LYB001 updates RSS · CI watch RSS
- Yantai Patronus Biotech Co., Ltd. portfolio CI